Detection of Functioning Thyroid Cancer Metastasis on Whole Body Pertechnetate Scintigraphy.
Main Article Content
Abstract
Thyrotoxicosis due to functioning metastases in differentiated thyroid cancer (DTC) is exceedingly rare. It may constitute confusing diagnostic as well as present therapeutic challenges. We present here two patients, a discussion and literature review on the subject. The patients presented initially with thyrotoxicosis and on routine 99mTc pertechnetate thyroid scan extrathyroidal foci of uptake were found, subsequently leading to the diagnosis of metastatic thyroid cancer. Histology showed both cases as follicular thyroid carcinoma. In one patient 18F-FDG displayed the metastases despite these foci exhibiting iodine avidity at an earlier 131-1 diagnostic scan. Both patients later received radioiodine in therapy doses. One patient had a pre-therapy total thyroidectomy. The other did not because of a relapse of his thyrotoxicosis even though he had been vigorously treated with anti-thyroid drugs. He received 131-1 therapy as palliation. Both patients are doing well on thyroxine replacement in suppressive doses and are being followed up. TC-99m pertechnetate whole body scan is showed here as useful in the detection of functioning distant metastases from differentiated thyroid carcinoma although 131-1 Whole Body Scan (WBS) is still generally considered the method of choice.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
How to Cite
References
1. Kasagi K, Takeuchi R, Miyamoto S, Misaki T, Inoue D, Shimazu A, Mori T, et al. Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. Clin Endocrinol, 1994; 40: 42934.
2. Basaria S, Salvatori R. Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Graves disease. | Endocrinol Invest, 2002; 25:63942
3. Girelli ME, Casara D, Rubello D, Pelizzo MR, Busnardo B, Ziliotto D. Severe hyperthyroidism due to metastatic papillary thyroid carcinoma with favorable outcome. J Endocrinol Invest, 1990; 13, 3337.
4. Guglielmi R, Pacella CM, Dottorini ME, Bizzarri GC, Todino V, Crescenzi A, et al. Severe thyrotoxicosis due to hyperfunctioning liver metastasis from follicular carcinoma: treatment with (131)1 and interstitial laser ablation. Thyroid, 1999, 9:1737.
5. Ikejiri K, Furuyama M, Muranaka T, Anai H, Takeo S, Sakai K, et al. Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis. Clin Nul Med, 1999; 22-22730,
6. Ishihara T, Ikekubo K, Shimodahira M, Iwakura T, Kobayashi M, Hino M, et al. A case of TSH receptor antibody-positive hyperthyroidism with functioning metastases of thyroid carcinoma. Endocr J, 2002;49:2415.
7. Lorberboym M, Mechanick JI. Accelerated thyrotoxicosis induced by iodinated contrast media in metastatic differentiated thyroid carcinoma. Nucl Med, 1996; 37: 15325.
8. Paul SJ, Sisson JC. Thyrotoxicosis caused by thyroid cancer. Endocrinol Metab Clin North Am, 1990; 19:593612
9. Salvatori M, Saletnich I, Rufini V, Dottorini ME, Corsello SM, Troncone L, et al. Severe thyrotoxicosis due to functioning. pulmonary metastases of well-differentiated thyroid cancer. / Nucl Med, 1998, 19: 12027
10. Seidlin SM. Marinelli LD, Oshry E Radioactive iodine therapy effect on functioning metastases of adenocarcinoma of the thyvid. CA Cancer) Clin, 410, 299317, 1990
11. Sisson JC, Carey E. Thyroid carcinoma with high levels of function: treatment with (131) (Nael Med, 2001:42 97583.
12. Smith R, Filum C. Bernua RS, Fawwaz RA Radioactive iodine treatment of metastatic thyroid carcinoma with clinical thyrotoxiconis. Clin Naud Med, 10,87451965
13. Yoshimura Nch 1, Mimura T, Kawano M, Hamada N. Ho K. Appearance of TSH receptor antibody and hyperthyroidiam amociated with metastatic thyroid cancer after total thyroidectomy. Andoer 1, 1997:44 8509,
14. Faivre-Defrance F. Carpentier P. DCC Dheebomez M. Leteurtre K, Marchandise X, et al. Thyrotoniconás revealing metastases of unrecognized thyroid cancer a report ontwo cases, Ann Eucherinol (Parts), 2007) : 380.0
15. Tan 1. Zhang C. Xu W. Meng 2, Dong Zhang F, et al. Thyrotoxicosis due to functioning metastatic follicular thyroid cancinoma after twelve 1131 therapies. Clin Nad Med, 2009:34:615-9
16 Grünwald F. Kälicke T. Feine U Lietzermayer R, Schetilhaser K, Dietlein M. et al. Flourine-18 fluorodeoxyglucose positinan emisam tomography in thyroid cancer results of a multicenter study, Eur/Nach Abd, 1999, 26: 1547-1552
17. Ivrich T. Barmer AR, Otto D, Hormann M. Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur/Nud Med Mol Imaging, 2012: 29:641-647
18. Wang W, Macapinlac H, Larson SM, YehSD, Akhart T, Firon RD, et al. [18F)-2-fluoro-2-deoxy-D-glucose positron emission. tomography localines residual thyroid cancer in patients with with negative diagnostic (131)1 whede body scans and elevated serum thyroglobulin levels, J Clin Endocrinol Metal 1999,84:2291-2302.
19. Wang W, Larson SM, Fazzari M. Tickoo SK, Kolbert K. Sgontos G, et al. Prognostic value of (185) Fluorodeoxyglucose positron
emission tomographic scanning in patients with thyroid cancer. J Clin Enderoul Metal, 2000, 85:1107-1113
20. Feine U, Listanmayer R, Hanke JP, Held J. Währie H. Müller-Schauenburg W Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Nael Med, 1996 371468-72
21. Tardy M, Tavernier E, Satot G Nove Jomsaratul R, Bournand C, Honszard C, et al. A case of hyperthyroidiun due to functioning metastasis of differentiated thyroid carcima. Discusion and hierature review Anar Eandorted (Pать), 2007, 68. 36-44
22. Leiter 1, Seidlin SM, Marinelli Letal Adenocarcinoma of the thyroid with hyperthyroidium and functional metastasen Clin Endocrinol, 1946, 6247-254
21. Mariotti Macchia 1, Pinchera A. Unanuاس form of thyrotondcosis. Inc Monaco F, Satta MA., Shapiro B, Troncone L, eds. Thyroid diwasens Clinical fundamentals and therapy. Boca Raton, FL: CRC Pro, 199181-90
24. Paul P, Son JC. Thyrotoxicosis canned by thyroid cans cancer. Endocrinol Metal Clin North Am, 1990,19,583-612
25. Turner JW, Spencer RP. Thyroid carcinoma presenting as pertechumetate "hot" nodule, baat without 1311 uptaker case report/NM 1976) 17:22-23
26. Tech KE, Davis L. Dremkin H. Papillary thyroid carcinoma concentrating both Te 99m sodium pertecnotate and 1-1M iodine case report and review of the literature Clos Naci Aled, 1991, 16:497-500.
27. Kalagiti M. Suzuki S, Sadahiro S, Kubouchi K. Ohimura T. Taumura O, et al. Accumulation of iodine-131 and technetium 99m portochimebate in thyroid carcinoma Clos Nad Mal, 1988:13:276-279
28 Donoghue CD, Steinbach JJ, Winterbergor AR. Unusual Te-99m and 1-123 images in metastatic thyrcád adenocarcinoma. Clin Nael Med, 1979, 4:468-470
29. Bouvier JF, You E. Peau JY, Chusard JL Lahneche HE Diffuse uptake of technetium 99m pertechnetate in a patient with metastases from thyroid carcinoma. Clim Nael Med, 1996:11:728-729.
30. Campbell CM. Khafagi FA Insensitivity of Tc-99m pertechnetate for detecting metastases of differentiated thyroid carcinoma, Clin Nucl Med, 1990; 15:1-4.
31. Ryo UY, Stachura ME, Schneider AB, Nichols R, Cogan SR, Pinsky S. Significance of extrathyroidal uptake of Tc-99m and 1-123 in the thyroid scan: concise communication. /Nucl Med, 1981;22:1039-1042.
32. Kumaresan K, Sastry RA. Localization of Te-99m pertechnetate in lymph node metastasis from occult thyroid carcinoma. Clin Nucl Med, 1994; 19:1112.
33. Krausz Y, Horne T. Detection of metastatic thyroid carcinoma by 99mTc-pertechnetate in the presence of hyperfunctioning thyroid tissue. J Surg Oncol, 1990; 44: 132-134.
34. Vieras F. Preoperative scintigraphic detection of cervical metastases from thyroid carcinoma with technetium-99m pertechnetate. Clin Nucl Med, 1985;10: 567-569.
35. McLaughlin RP, Scholz DA, McConahey WM, Childs DS Jr.. Metastatic thyroid carcinoma with hyperthyroidism: two cases with functioning metastatic follicular thyroid carcinoma. Mayo Clin Proc, 1970:45:328-335.
36. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (insular) thyroid carcinoma. A re-interpretation of Langhans 'wuchernde
struma'. Am J Surg Pathol, 1984;8: 655-68,
37. Freeman LM. In: Freeman (ed), Freeman and Johnson's Clinical radionuclide Imaging. Orlando; Rune & Stratton, 1984; 1292-1295,
38. Valenta L. Metastatic thyroid carcinoma in man concentrating iodine without organification. J Clin Endocrinol Metab, 1966; 26: 1317-24,
39. Lind P, Kresnik E, Kumnig G, Gallowitsch HJ, Igerc I, Matschnig S, et al. 18F-FDG-PET in the follow up of thyroid cancer. Acta Med Austriaca, 2003; 30: 17-21.
40. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, et al. Expression of the Na+/1 symporter gene in human thyroid tumors:
a comparative study with other thyroid specific genes. Clin Endocrinol Metab, 1999; 84: 3228-3234.
41. Grünwald F, Biersack HJ. FDG PET in thyroid cancer: thyroxine or not? J Nuel Med, 2000; 41: 1996-1998.
42. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol, 2002; 37: 169-74.